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Growth factors are a class of signaling proteins that direct cell fate through interaction with cell-surface
receptors. Although a myriad of possible cell fates stems from a growth factor binding to its receptor, the
signaling cascades that result in one fate over another are still being elucidated. One possible mechanism
by which nature modulates growth factor signaling is through the method of presentation of the growth
factor – soluble or immobilized (matrix bound). Here we present the methodology to study signaling of
soluble versus immobilized VEGF through VEGFR-2. We have designed a strategy to covalently immo-
bilize VEGF using its heparin-binding domain to orient the molecule (bind) and a secondary functional
group to mediate covalent binding (lock). This bind-and-lock approach aims to allow VEGF to assume
a bioactive orientation before covalent immobilization. Surface plasmon resonance (SPR) demonstrated
heparin and VEGF binding with surface densities of 60 ng/cm2 and 100 pg/cm2, respectively. ELISA
experiments conﬁrmed VEGF surface density and showed that electrostatically bound VEGF releases in
cell medium and heparin solutions while covalently bound VEGF remains immobilized. Electrostatically
bound VEGF and covalently bound VEGF phosphorylate VEGFR-2 in both VEGFR-2 transfected cells and
VEGFR-2 endogenously producing cells. HUVECs plated on VEGF functionalized surfaces showed
different morphologies between surface-bound VEGF and soluble VEGF. The surfaces synthesized in
these studies allow for the study of VEGF/VEGFR-2 signaling induced by covalently bound, electrostat-
ically bound, and soluble VEGF and may provide further insight into the design of materials for the
generation of a mature and stable vasculature.
 2009 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Tissue engineering and tissue regeneration approaches pres-
ently suffer from oxygen and nutrient delivery constraints because
of the inability of current scaffolds to guide the formation of stable
and long lasting vascular networks [1]. Cells seeded or residing in
the middle of the tissue construct have a limited supply of oxygen
and nutrients since blood vessels are not inﬁltrating at an appre-
ciable rate, and the diffusion limit of oxygen is only a few hundred
microns [2]. Vascular endothelial growth factor (VEGF) is a key
component in the signaling cascade to form new blood vessels from
existing vessels and can trigger proliferation, migration, and
survival of cells through a single growth factor-receptor binding
event [3]. Because of alternative splicing, VEGF can exist as manyLos Angeles, Chemical and
Plaza, 5531 Boelter Hall, Los
Y-NC-ND license.different isoforms with different afﬁnities for the extracellular
matrix (ECM). For example, VEGF165 binds to the ECM while
VEGF121 remains soluble. VEGF165 contains a 55 amino acid long
heparin-binding domain located at the C-terminus end of the
protein and is coded by exons 6 and 7 of the VEGF gene [4]. The
afﬁnity of VEGF for the ECM has been shown to regulate angio-
genesis and the morphology of the blood vessels formed. In pros-
tate cancer, the ratio of VEGF121/VEGF165–189 increases as tumor
angiogenesis increases [5] and the enhanced release of VEGF165
from the ECM by matrix metalloproteinases and plasmid has been
shown to increase angiogenesis in colorectal cancer [6]. Further,
VEGF immobilized to three dimensional matrices leads to the
formation of smaller, structured capillary networks, while encap-
sulated (soluble) VEGF165 leads to the formation of large, leaky
blood vessels in vivo [1,7,8]. Last, VEGF165 that is immobilized in two
dimensions shows enhanced endothelial cell proliferation and
migration in vitro [9–12].
Differences in cell biology as a result of cells being in contact
with soluble versus immobilized growth factors are not unique to
VEGF. Studies using immobilized epidermal growth factor (EGF)
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immobilized and soluble growth factors [13,14]. Further, studies
with covalently immobilized EGF to cell culture substrates via
a tresyl chloride mediated binding have shown that the growth
factor is still able to phosphorylate the EGF receptor [14], suggest-
ing that receptor internalization is not needed to activate the
receptor and induce downstream signaling. The ability to phos-
phorylate cell-surface receptors from covalently immobilized
cytokines was also observed between epoxy immobilized Gran-
ulocyte Macrophage Colony Stimulating Factor (GM-CSF) and its
receptor, STAT5 [15].
Protein immobilization has been investigated through the use of
unspeciﬁc chemistry such as amine/carboxylic acid chemistry
[9,16,17] and thiol chemistry [18], or through the use of biological
interactions such as biotin–avidin [19]. However, these approaches
result in the immobilized protein being bound through different
conformations on the surface and result in reduction of protein
activity [20]. Approaches to immobilize proteins with uniform
orientation typically involve the engineering and production of the
protein using recombinant techniques to introduce ligands for
speciﬁc receptors [10,20] or functional groups such as thiols at
speciﬁc locations in the protein [21]. Alternatively, the natural
afﬁnity of growth factors for the extracellular matrix, especially
heparin binding, has been exploited to electrostatically bind
growth factors to natural [22,23] or synthetic [24–26] hydrogels
and to heparin-modiﬁed hydrogels and surfaces [22,23,26,27].
Heparin binding has the advantage that the protein does not have
to be modiﬁed and that the natural binding afﬁnity of the growth
factor for the ECM can be exploited. Immobilization of proteins to
glass through silane chemistry [28] or gold through self-assembled
monolayers (SAMs) [20,29–31] has been extensively used with the
above-mentioned strategies. Gold substrates are especially attrac-
tive for protein immobilization because SAM forming thiols are
available with a variety of functional groups and the quantiﬁcation
of the immobilized molecules, polymers, and proteins can be
characterized using surface plasmon resonance (SPR).
Although studies have begun to point out the differences in
cellular behavior due to the afﬁnity of VEGF165 (referred to as VEGF
from now on) for the ECM, strategies to compare VEGFR-2 phos-
phorylation and downstream signaling as a function of the afﬁnityFig. 1. Cartoon of our bind-and-lock immobilization strategy for VEGF. VEGF is incubated wit
binding domain of VEGF (A). For covalent immobilization the heparin-modiﬁed surface also c
(B). Thus, this approach uses speciﬁc electrostatic (non-covalent) interactions ﬁrst to orient t
to keep it in place (lock).of VEGF for the matrix are not available. Our objective in this report
was to synthesize surfaces that contained either electrostatically or
covalently bound VEGF and to determine if covalently immobilized
VEGF was able to phosphorylate VEGFR-2. Our strategy to immo-
bilize VEGF takes advantage of the heparin-binding domain at the
C-terminus of the protein to orient the growth factor on the surface
and a photoreactive group to covalently bind the growth factor to
the surface in that orientation (bind-and-lock approach, Fig. 1).
Heparin was oxidized, modiﬁed with a photoreactive group, and
immobilized to an amine containing SAM on gold surface through
reductive amination. VEGF was then allowed to electrostatically
bind to the heparin-modiﬁed surface and then the surface was
exposed to UV light to covalently immobilize (lock) the growth
factor into place. Heparin without the photoreactive group was
used as a control, which resulted in VEGF that was only electro-
statically bound through its heparin-binding domain. For cellular
experiments, ﬁbronectin (FN) was used to backﬁll the surface. This
approach offers the ability to study VEGF signaling using VEGF that
has three different afﬁnities for the ECM – covalent (high), elec-
trostatic (medium) and soluble (low).
2. Materials and methods
2.1. Materials
(1-Mercapto-11-undecyl) tetra (ethylene glycol) (EG-OH) was purchased from
Asemblon (Redmond, WA). (1-Mercapto-11-undecyl) septa (ethylene glycol) amine
(EG-NH2) was obtained from ProChimia (Evanston, IL). Heparin sodium salt from
porcine intestinal mucosa was purchased from Alfa Aesar (Ward Hill, MA). Vascular
Endothelial Growth Factor (VEGF) was purchased from Shenandoah Biotechnology
(Warwick, PA). Porcine aortic endothelial (PAE/KDR) cells overexpressing KDR, the
human isoform of VEGFR-2, were provided by Dr. Gera Neufeld of Technicon, Israel.
Human umbilical vein endothelial cells (HUVECs) were a kind gift from Dr. Andy
Putnam of UC Irvine. All other reagents and products were purchased from Fisher
Scientiﬁc unless noted otherwise.
2.2. Cell culture
PAE/KDR cells were cultured in F-12 (Invitrogen, Grand Island, NY) medium
supplemented with 10% bovine growth serum (BGS, Hyclone, Logan, UT) and 1%
penicillin/streptomycin (Invitrogen, Grand Island, NY) at 37 C and 5% CO2. HUVECs
were cultured in EGM-2 complete medium (Lonza, Basel, Switzerland) at 37 C and
5% CO2. Both cell types were split using trypsin following standard protocols and
were typically used up to passage 10.h a heparin-modiﬁed surface and allowed to electrostatically bind through the heparin-
ontains a photoreactive group, p-azidobenzoyl, that can be activated post-VEGF binding
he growth factor through its heparin-binding domain (bind) and then a covalent bond
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Heparin was modiﬁed with the photoreactive group p-azidobenzoyl by ﬁrst
oxidizing heparin using sodium periodate (NaIO4) to introduce aldehyde groups
throughout the heparin backbone and then reacting the oxidized heparin with
a heterobifunctional crosslinker that reacts with aldehydes on one end and contains
the photoreactive group on the other end. Heparin (62.5 mg/ml) was mixed with
a solution of NaIO4 (200 mM) in 100 mM sodium acetate buffer (pH 5) and incubated
for 2 days at 4 C to allow the reaction to occur. The reaction mixture was puriﬁed
through dialysis (3500 MWCO), lyophilized and stored as a powder at 4 C until
used. Oxidized heparin (3 mg/ml) was mixed with p-azidobenzoyl hydrazide (ABH,
Pierce, Rockford, IL, 0.65 mM) in PBS buffer (pH 7.4) for 2 h and the reaction mixture
puriﬁed through dialysis. The ﬁnal product was lyophilized and stored as a powder
at 4 C in the dark. Oxidized heparin was characterized through infrared spectra
using an FTIR spectrometer (Jasco FT/IR-420). Heparin-ABH was characterized
through UV absorbance at 290 nm in a Beckman Coulter DU 730 (Fullerton, CA).
2.4. Gold evaporation and self-assembled monolayer (SAM) formation
Gold substrates were generated by e-beam evaporation resulting in 30 nm
thick gold on a 5 nm titanium adhesion layer over standard laboratory glass slides
following a piranha clean. Gold substrates were cleaned once with acetone and
twice with sterile 200 proof ethanol, dried under argon or nitrogen, and
immersed in a 2 mM solution of 1% EG-NH2 and 99% EG-OH for 18 h. Following the
incubation, the gold substrates were washed with ethanol twice and dried under
argon or nitrogen. Contact angle and ellipsometry measurements were obtained
to verify SAM formation and stability against long wave UV light. Contact angles
were measured using a goniometer (Newport VPH-2, First Ten Angstroms, Inc.)
and ellipsometry measurements were taken with a SopraGES5 ellipsometer (Palo
Alto, CA).
2.5. Heparin and VEGF immobilization
Heparin-ABH was immobilized to an amine containing SAM surface through the
formation of a Schiff base between the aldehyde groups in heparin and the amines
on the SAM surface, followed by reductive amination to form an irreversible bond.
Heparin-ABH (1 mg/ml) was incubated on a 1% EG-NH2 SAM surface for 24 h at 4 C,
followed by a sodium cyanoborohydride incubation (50 mM in 100 mM sodium
acetate pH 4) for 5 min at room temperature. The remaining aldehydes on the
immobilized oxidized heparinwere quenched with 500 mM Tris (pH 8) for 10 min at
room temperature, followed by another sodium cyanoborohydride 5 min incuba-
tion. The heparin-modiﬁed surfaces were then washed two times with 0.05%
Tween-20 in PBS and two times with PBS to remove non-speciﬁcally bound heparin
and immediately used to immobilize VEGF. Heparin-modiﬁed SAM surfaces were
incubated with VEGF (200 ng/ml in PBS) for 24 h at 4 C, washed with PBS, and
exposed to UV light (365 nm, UVL-54, UVP, Upland, CA) for 10 min. The resulting
VEGF-modiﬁed surfaces were washed three times with 0.05% Tween-20 in PBS and
incubated for up to 2 days in a heparin containing solution (1 mg/ml heparin in
0.05% Tween-20 in PBS) at 4 C to release all non-speciﬁcally bound VEGF, followed
by a PBS wash. VEGF surfaces that did not contain ABH were formed following the
same protocol, but oxidized heparin was used instead of heparin-ABH and 0.05%
Tween-20 in PBS was used for the release step rather than the heparin solution. All
surfaces were immediately used.
2.6. Heparin and VEGF binding density analysis
A Biacore T100 Molecular Interaction System (GE, Amersham Biosciences,
Pittsburgh, PA) was used to characterize the binding of heparin and VEGF to amine
functionalized surfaces. 1 cm 1.2 cm gold chips were purchased from Biacore and
functionalized to form 1% EG-NH2 SAMs as described above. The surfaces were
primed with ﬁltered PBS (pH 7.4) and the baseline was allowed to stabilize at 5 ml/
min. Oxidized heparin (1 mg/ml) was injected at 5 ml/min for 30 min followed by
sodium cyanoborohydride (100 mM) in 100 mM sodium acetate (pH 4) at 5 ml/min for
7 min. Tris buffer (100 mM, pH 8) was subsequently injected at 5 ml/min for 6 min.
Two 0.05% Tween-20 in PBS (pH 7.4) injections at 5 ml/min for 5 min each were used
as washes. VEGF (200 ng/ml) was injected at 5 ml/min for 15 min. Between injections
and after the ﬁnal injection, the signal was allowed to stabilize for 5–10 min with
continuous ﬂow of ﬁltered PBS (pH 7.4) at 5 ml/min.
2.7. Cellular characterization of the surface
Cell attachment and spreading on the surface were used to study the protein
adsorption properties of the surface. Human plasma ﬁbronectin (Sigma–Aldrich,
Saint Louis, MO)was incubated on the SAM surface (100% EG-OH or 1% EG-NH2, with
and without heparin) at 20 mg/ml for 2 h at 4 C followed by a 30 min 1% BSA–PBS
block step. PAE/KDR cells were plated without serum at 500,000 cells/ml for 20 min
for the attachment assay and allowed to spread for 2 h for the spreading assay. After
the experiment was complete, the cells were washed with PBS and ﬁxed with 4%
paraformaldehyde. Following 0.1% Triton X-100 treatment and a 1% BSA blockingstep, the cells were incubated with HOESCHT and phalloidin-Alexa488 (Invitrogen,
Carlsbad, CA). Images were acquired on a Zeiss microscope and quantiﬁed with
ImageJ software by counting cells and analyzing their spread area with the tracer
function.
2.8. VEGF release kinetics and surface quantiﬁcation
To quantify the release kinetics of VEGF from the surface and the amount of
VEGF immobilized to the surface, a standard ELISA technique was used. A high
binding 96-well plate was incubated overnight at room temperature with 1 mg/ml
VEGF capture antibody (R&D Systems, Minneapolis, MN). After incubating the
surface with blocking buffer (1% BSA in PBS, pH 7.4) for 1 h at room temperature,
release samples were incubated for 2 h with the ELISA plate at room temperature.
Following washes with washing buffer (0.05% Tween-20 in PBS, pH 7.4), the surface
was incubated with a biotinylated detection antibody (1 mg/ml in blocking buffer,
R&D Systems, Minneapolis, MN) for 2 h at room temperature. Finally, the surface
was incubated with streptavidin–HRP (200 mg/ml in blocking buffer, R&D Systems,
Minneapolis, MN) for 20 min at room temperature and, after washing, was exposed
to TMB substrate (Cell Signaling Technology, Beverly, MA) for 20 min at room
temperature. The resulting absorbance was read at 645 nm in a plate reader (BioTek
PowerWave XS, Winooski, VT). To determine the amount of VEGF directly bound to
the surface, a similar procedure was used, except that the biotinylated detection
antibody incubation step was done directly on the VEGF-modiﬁed surface. The
release solutions contained 0.1% BSA to stabilize VEGF, and the surfaces werewashed
with washing buffer prior to the assay.
2.9. Surface-bound VEGF activity assay
A standard Western blot procedure with minor modiﬁcations was used to
investigate the ability of surface-bound VEGF to phosphorylate VEGFR-2. To adopt
a method suitable for surface analysis, PAE/KDR cells were passed and plated at full
conﬂuency onto amine functionalized poly-dimethoxy silane (PDMS) sheets in 10%
BGS supplemented F-12 media the day before cell treatment. To make the PDMS
sheets, PDMS and initiator weremixed in a 10:1 v/v ratio, degassed, and poured onto
0.75 mm gel-casting plates. The mixture was then placed in an 110 C oven for 10–
15 min to cure. The PDMS sheet was removed from the gel-casting plates and
washed with ethanol and DI water. The surface of the PDMS sheet was activated in
a 50% v/vmethanol, 50% v/v hydrochloric acid solution for 30 min. The surfaces were
then dried under a stream of nitrogen or argon and placed in a 5% v/v APTES in
ethanol solution overnight. Subsequently, the PDMS sheets were washed in ethanol
and water, then dried again under inert stream and placed in the oven for 10–
15 min. Following the previously mentioned overnight incubation with cells, the
cells on the PDMS sheets were incubated with serum-free medium for 6 h, then
incubated in 0.1 mM Na3VO4 (in serum-free medium) for 5 min to inhibit phos-
phatase activity. VEGF functionalized slides, following overnight storage in release
solutions, were incubated with ﬁbronectin (20 mg/ml) for 2 h at 4 C, then BSA for
30 min at 4 C to block non-speciﬁc binding sites. The PDMS sheets with cells were
ﬂipped over onto the VEGF functionalized gold slide for a 30 min treatment at 37 C.
The cell treatment was terminated by removal of the PDMS sheet from the VEGF
functionalized gold slide followed by washes with cold PBS (pH 7.4) supplemented
with 0.2 mM Na3VO4. Cells were removed from the PDMS sheet by incubation with
lysis buffer (1% Triton X-100, 10 mM Tris–HCl, pH 7.6, 150 mM NaCl, 30 mM sodium
pyrophosphate, 50 mM sodium ﬂuoride, 2.1 mM sodium orthovanadate, 1 mM EDTA,
1 mM phenylmethylsulfonyl ﬂuoride, and 2 mg/ml of aprotinin) for 15 min at 4 C.
Insoluble cell material was removed by centrifugation at 4 C for 5 min at
14,000 rpm (Beckman Coulter Microfuge 22R). Equal amounts of cell lysate (BCA
assay, Bio-Rad) were diluted in 5 loading buffer (1 M Tris–HCl, pH 6.8, 20% SDS, 50%
glycerol) supplementedwith 5% (v/v) b-mercaptoethanol, boiled for 10 min at 70 C,
separated by SDS-PAGE (8% resolving, 2 h at 130 V), and transferred to nitrocellulose
membranes (2 h at 400 mA). The membranes were incubated in blocking buffer (5%
milk in 0.1% Tween-20 in TBS) for 1 h at room temperature before overnight incu-
bation with primary antibodies. Phosphorylated proteins were detected by immu-
noblotting using anti-phosphotyrosine antibodies (1 mg/ml pY20, Santa Cruz
Biotechnology, in blocking buffer) followed by secondary antibodies coupled with
horseradish peroxidase (200 ng/ml, Invitrogen, 1 h at room temperature) and
visualized by chemiﬂuorescence (ECL detection reagents, GE Healthcare) using
a Typhoon scanner (GE, Amersham Biosciences). Protein-loading control was
assessed by Western blot using anti-VEGFR-2 (Cell Signaling Technology). Typhoon
images were analyzed and normalized with ImageJ software. Statistical comparisons
were done with 5 independent experiments. HUVEC VEGFR-2s (endogenous) were
activated following the same method, except the cells were allowed to reach con-
ﬂuency on the functionalized PDMS sheets and the cells were treated for both 5 and
30 min. pVEGFR-2 (1175) (Cell Signaling Technology, Beverly, MA) was used to detect
levels of endogenous VEGFR-2 phosphorylation.
2.10. Cellular proliferation and quantitative ﬂuorescent microscopy
To investigate if surface-bound VEGF and soluble VEGF result in different cell
proliferation rates ormorphologies, cell counting and immunocytochemical staining
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bated with 20 mg/ml of ﬁbronectin for 2 h at 4 C, then incubated with 1% BSA (in
PBS, pH 7.4) to block non-speciﬁc binding sites. After two sterile PBS (pH 7.4) washes,
HUVECs were plated at 30,000 cells/well. For cell proliferation experiments, cells
were grown in basal EGM-2 media with fetal bovine serum, while cell morphology
experiments were performed in the same media supplemented with a cocktail of
growth factors, but without VEGF (Lonza, Basel, Switzerland). In the positive control,
cells were plated on heparin-functionalized surfaces and treated with 200 ng/ml of
soluble VEGF, provided fresh with each media change. After ﬁve days, the cells were
ﬁxed with 4% paraformaldehyde for 30 min at room temperature, permeabilized
with 0.1% Triton X-100 (in PBS, pH 7.4) for 3 min at room temperature, and blocked
with 1% BSA (in PBS, pH 7.4). The cells were incubated with mouse anti-PECAM
(Santa Cruz Biotechnology, Santa Cruz, CA) according to manufacturer’s instructions
for immunocytochemistry. After three 0.05% Tween-20 (in PBS, pH 7.4) washes, the
cells were incubated with phalloidin-Alexa488, HOESCHT, and goat anti-mouse
Alexa 555 (Invitrogen, Carlsbad, CA) staining solution for 1 h at room temperature.
The surfaces were washed, covered with mounting solution (50% DI water, 50%
glycerol), and imaged with a Zeiss Observer microscope (Thronwood, NY). Red,
green, and blue exposure times were 600, 200, and 40 ms, respectively. Proliferation
was quantiﬁed by counting the number of cells remaining after 5 days as previously
mentioned. The morphology images were quantiﬁed for PECAM-1 intensity in
ImageJ software by measuring the intensity of red ﬂuorescence and then normal-
izing by the number of cells based on nuclei (blue stain) present in each photo.
Triplicates of each condition were performed with 5 photos per well (total n¼ 15).
The experiment was performed independently 3 times, with the same observed
trends, and representative results were displayed.
2.11. Statistical analysis
Data are presented as mean standard deviation. To identify signiﬁcant trends
in data, statistical comparisons were performed by one-way ANOVA with post-test
using the Tukey method. Data were considered signiﬁcantly different if p< 0.05.3. Results
3.1. Heparin immobilization and surface characterization
Heparin modiﬁcation was tracked by infrared spectroscopy (IR)
and UV–vis absorbance spectroscopy. After oxidation, a sharp peak
at 1730 cm1 was found through IR, indicating that a carbon–
oxygen double bond was formed (Fig. 2). The incorporation of ABH
was conﬁrmed through monitoring the increase in UV absorption
at 290 nm after modiﬁcation and comparing to unmodiﬁed
heparin. The UV absorption increased from 0.168 0.026 to
0.615 0.158, indicating the modiﬁcation of heparin with ABH.
To ensure gold and titanium layer deposition as well as SAM
formation and stability, ellipsometry was used to quantify any
increase or decrease in surface thickness. Gold and titanium layer
deposition resulted in an increase in surface thickness of 30 nm andFig. 2. Infrared spectra of unmodiﬁed heparin (solid line) and oxidized heparin (dotted
line). The oxidation of heparin was tracked by appearance of a sharp peak at 1730 cm1
(arrow).5 nm, respectively (data not shown). Further, the surface thickness
increased as a result of SAM formation for 1% EG-NH2 (99% EG-OH,
Fig. 3A) and 100%EG-OH (Fig. 3B) surfaces as expected. Since the SAM
surfaces were exposed to long wave UV light during the covalent
immobilization strategy for VEGF, the stability of the SAM surface
upon exposure to long wave UV light was characterized. SAM
surfaces were exposed to long wave UV light for 10 min while
submerged in PBS (pH 7.4). UV treatment did not affect the thickness
of a 1% EG-NH2 SAM layer (Fig. 3A), showing that the SAMwas intact.
As a control, a 100% EG-OH SAM surface was submerged in piranha
solution, which was expected to result in the complete stripping of
the SAM layer. The piranha clean etched the surface (Fig. 3B) as
denoted by the negative vertical displacement of the plot.
Water droplet contact angle goniometry showed a contact angle
of 73.83 5.17 for bare gold, 33.410.74 for EG-OH-modiﬁed
surfaces, and 30.801.75 for 1% EG-NH2-modiﬁed surfaces indi-
cating that the surfacewasmodiﬁed since the surface becamemore
hydrophilic. Further, ultraviolet light treatment did not affect the
contact angle (33.27 0.65), which further supports that UV
treatment did not adversely affect SAM surface integrity. The
piranha clean, on the other hand, restored the surface hydropho-
bicity observed for the unmodiﬁed gold surface (62.80 0.39).
The speciﬁc immobilization of heparin to a 1% EG-NH2 surface
was studied through SPR (Fig. 4). Oxidized heparin was injected
onto a 1% EG-NH2 surface or a 100% EG-OH control to quantify theFig. 3. (A) Ellipsometry plot of unmodiﬁed gold and EG-NH2-modiﬁed gold before and
after UV treatment. (B) Ellipsometry plot of unmodiﬁed gold and EG-OH-modiﬁed gold
before and after piranha clean. Both EG-NH2 and EG-OH modiﬁcation was tracked
through the positive displacement in the ellipsometry plot. UV treatment did not affect
the EG-NH2 SAM, while piranha clean removes the EG-OH SAM and etches the surface.
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demonstrates that oxidized heparin has a higher afﬁnity for the 1%
EG-NH2 surface than the EG-OH surface (light curve), as expected.
Further, following the washing and reductive amination steps, the
mass observed on the EG-OH surface was completely removed
(Fig. 4B–D light curve), indicating that the heparin binding
observed can be easily washed off. In contrast, the EG-NH2 surface
retained 600 response units (RU) after the washing and reductive
amination steps, which correspond to 60 ng/cm2 of immobilized
heparin and conﬁrmed the speciﬁc binding of heparin to the
surface. The steep change in baseline (refractive index) during the
sodium cyanoborohyride injection and the Tris injection (Fig. 4B
and C) occurred due to the changes in the pH and ionic strength of
the solutions.
To further conﬁrm that heparin modiﬁcation and immobiliza-
tion occurred and that the resulting surface was able to support cell
attachment and spreading, PAE/KDR cells were cultured on the
modiﬁed surfaces previously coated with ﬁbronectin. PAE/KDR
attachment and cell spreading on 100% EG-OH surfaces with and
without heparin incubation resulted in statistically reduced
attachment (p< 0.001) compared to bare gold, heparin-modiﬁed
surfaces, and tissue culture plastic (Fig. 5). PAE/KDR attachment on
1% EG-NH2 surfaces was statistically different from tissue culture
plastic (p< 0.05), but not from bare gold or heparin-modiﬁed
surfaces (Fig. 5A). Cell spreading on 1% EG-NH2 surfaces was
statistically different (p< 0.001) from bare gold, heparin-modiﬁed
surfaces and tissue culture plastic (Fig. 5C, F, G, H), indicating that
even though the cells were able to attach to the 1% EG-NH2 surface,
the cells were not fully spread compared to the test condition and
positive controls (Fig. 5F). The heparin-modiﬁed surfaces resulted
in similar cell attachment and spreading (p> 0.05) than that
observed for bare gold and tissue culture plastic. Taken together,
this data shows that the heparin-modiﬁed surfaces are non-toxic
and can support ﬁbronectin binding and cell growth.3.2. VEGF immobilization
The speciﬁc immobilization of VEGF to heparin-modiﬁed SAM
surfaces was studied through SPR and ELISA. VEGF (200 ng/ml) was
injected to surfaces that underwent the heparin immobilizationFig. 4. Surface plasmon resonance (SPR) for oxidized heparin immobilization to EG-
NH2 and EG-OH functionalized surface. SPR steps are: (A) heparin injection (1 mg/ml,
30 min), (B) sodium cyanoborohydride injection (100 mM, 7 min), (C) Tris injection
(100 mM, 6 min), and (D) Tweenwashes (0.05% in PBS, 5 min/each). Data indicated that
heparin is stably bound at about 60 ng/cm2. All injections were done at 5 ml/min and
PBS was used between injections to wash and stabilize the baseline. Following all the
injections, oxidized heparin was only immobilized to the surface that contained
amines, indicating that 1% EG-NH2 surface is sufﬁcient for heparin immobilization.steps described above or that contain only the 1% EG-NH2 surface.
The shape of the response unit curve versus time indicates that
VEGF binds to the heparin-modiﬁed surface with higher afﬁnity
than the 1% EG-NH2 surface (Fig. 6E and ﬁgure inset). To quantify
the density of VEGF on the heparin-ABH-modiﬁed surface, a direct
ELISA method was employed, using a 1% EG-NH2 surface and
immobilized oxidized heparin as controls. To ensure only speciﬁ-
cally immobilized VEGF was measured, the surfaces were incu-
bated in PBS until the release of non-speciﬁcally bound VEGF was
minimal as measured by ELISA readings. VEGF bound at densities of
197.82 9.00,166.1518.38, and 120.05 9.60 pg/cm2 for surfaces
modiﬁed with heparin-ABH, oxidized heparin, and 1% EG-NH2,
respectively, before any release. The release proﬁle in PBS showed
that both heparin-ABH and oxidized heparin surfaces had up to 40%
release during the ﬁrst 3 days of release before leveling off (Fig. 7A),
which resulted in about 100 pg/cm2 of VEGF immobilized to the
surface at the end of 5 days of release (Fig. 7B). In contrast, EG-NH2
surfaces released up to 80% during the 2 days of release and
resulted in a VEGF surface density of 20 pg/cm2 (p< 0.05), indi-
cating that the binding is unspeciﬁc and unfavorable.
To investigate the stability of bound VEGF and to determine if
there is an advantage to the introduction of the ABH crosslinker to
the heparin surface, release kinetics were studied in a solution
containing free heparin and in PAE/KDR cell conditioned media.
VEGF immobilized through its heparin-binding domain only
(Fig.1A) resulted in signiﬁcantlymore releasewhen the surfacewas
incubated in 1 mg/ml heparin or in PAE/KDR cell conditioned
media than when incubated in PBS (p< 0.05, Fig. 7C). In contrast,
VEGF immobilized covalently (Fig. 1B) did not show any additional
release when incubated in heparin or PAE/KDR conditioned media
when compared to PBS (Fig. 7C). These results show that immo-
bilization through the heparin-binding domain is not sufﬁcient to
prevent the release of VEGF in complexmixtures that competewith
VEGF for the same binding sites. Direct ELISA measurements per-
formed after 5 days of release conﬁrmed that 100 pg/cm2 of VEGF
was bound for the covalent binding condition under all release
conditions, while 70 pg/cm2 of VEGF was bound for the heparin-
binding domain only condition (p< 0.05, Fig. 7D).
3.3. VEGF activity
To determine if VEGF retained its activity to phosphorylate
VEGFR-2 post-covalent immobilization, the phosphorylation of
VEGFR-2 was studied in PAE/KDR cells. Because the degree of
attachment and spreading of the cells can affect their phosphory-
lation proﬁle, cells were grown on ﬂexible PDMS sheets until
conﬂuency was reached. The cell sheets were then ﬂipped and
placed on top of VEGF-modiﬁed surfaces for 30 min after which
time the cells were lysed and the protein concentration measured.
Western blot analysis was used to quantify the phosphorylation of
VEGFR-2 induced by covalently immobilized, electrostatically
immobilized or soluble VEGF (Fig. 8A). The same level of phos-
phorylation was observed for electrostatically and covalently
immobilized VEGF. In contrast, surfaces that contained heparin and
ﬁbronectin but no VEGF resulted in lower VEGFR-2 phosphoryla-
tion as expected (p< 0.05). Soluble VEGF was used as a positive
control at a concentration of 200 ng/ml.
To investigate if covalently immobilized VEGF was able to
induce the phosphorylation of endogenously expressed VEGFR-2,
we investigated VEGFR-2 phosphorylation in HUVECs. The same
PDMS sheet approach to culture the cells and place the cells in
contact with the VEGF-modiﬁed surfaces mentioned above was
used to study VEGFR-2 phosphorylation in HUVECs. Both covalently
and electrostatically bound VEGF were able to phosphorylate
VEGFR-2 (Fig. 8B). Interestingly, the level of phosphorylation did
Fig. 5. Cell attachment and spreading on heparin-modiﬁed surfaces show ability to adhere ﬁbronectin and support cell growth. (A) Cell attachment on bare gold (BG), SAMs
functionalized with EG-OH, EG-OH/heparin, EG-NH2 and EG-NH2/heparin, and tissue culture plastic (TC). (B) Cell spreading on bare gold, SAMs functionalized with EG-OH, EG-OH/
heparin, EG-NH2 and EG-NH2/heparin, and tissue culture plastic (TC). Cells were stained for actin (green) and nucleus (blue) for cells seeded on (C) bare gold surface and SAMs
functionalized with (D) EG-OH, (E) EG-OH/heparin, (F) EG-NH2, and (G) EG-NH2/heparin. As an additional control, cells were seeded on tissue culture plastic (H). Scale bar is 100 mm.
The symbol *** indicates statistical signiﬁcance to a level of p< 0.001 using one-way ANOVA with a Tukey post-hoc test, which compares all possible pairs.
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Fig. 6. Surface plasmon resonance (SPR) data of VEGF binding to a heparin or 1% EG-NH2 surface. SPR steps are: (A) heparin (1 mg/ml) or PBS injection (30 min), (B) sodium
cyanoborohydride injection (100 mM, 7 min), (C) Tris injection (100 mM, 6 min), (D) Tween washes (0.05% in PBS, 5 min/each), and (E) VEGF injection (200 ng/ml, 15 min). The
bottom plot represents a close up view of the dotted square in the top plot, which shows the VEGF binding step. VEGF did not bind to the 1% EG-NH2 surface in the absence of
heparin, with the baseline returning to the initial value. For surfaces that contained heparin, VEGF was bound at 100 pg/cm2. All injections were done at 5 ml/min and PBS was used
between injections to wash and stabilize the baseline.
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ically immobilized cases as it did for the soluble VEGF condition
between the 5 and 30-min incubations (Fig. 8B).
To further conﬁrm that immobilized VEGF remained active post-
immobilization and to begin to study differences in cellular
responses that soluble versus immobilized VEGF induce, HUVECs
were cultured directly on top of VEGF-modiﬁed surfaces and
analyzed for proliferation and gap junction formation. HUVECs
were allowed to grow in media with either no growth factors
(proliferation) or supplemented with growth factors (minus VEGF,
morphology) on the surface for 5 days before the cells were ﬁxed
and stained for gap junctions (PECAM-1), actin cytoskeleton
(phalloidin) and nucleus (HOESCHT). Both electrostatic and cova-
lently bound VEGF resulted in statistically increased cellular
proliferation compared to the no VEGF control (p< at least 0.05,
Fig. 9). However, cellular proliferation was statistically higher for
the soluble VEGF condition (p< at least 0.05). At day 5, all the
conditions showed organized morphology, with covalently bound
VEGF, electrostatically bound VEGF, and no VEGF showing cobble-
stone morphology (Fig. 10A–C). Soluble VEGF treatment led to
elongated and aligned cells (Fig. 10D). The quantiﬁcation of the
PECAM staining normalized to the number of cells showed thatcovalently bound VEGF, electrostatically bound VEGF, and soluble
VEGF had increased PECAM intensity over the no VEGF condition
(p< at least 0.05, Fig. 10E).4. Discussion
Although VEGF has been shown to result in different cellular
behaviors depending on its afﬁnity for the extracellular matrix,
strategies to study the intracellular signaling that results from cells
stimulated by soluble versus immobilized VEGF are limited. The
study of immobilized VEGF signaling would offer insight into the
process of blood vessel formation and how to better engineer tissue
engineering scaffolds that can blend with the host vasculature. In
this report, we explored a strategy to immobilize VEGF covalently
and electrostatically to heparin-modiﬁed surfaces in an effort to
generate surfaces that could be used to study VEGFR-2 downstream
signaling and cellular responses as a result of immobilized VEGF.
We showed that covalently bound VEGF could induce VEGFR-2
phosphorylation to a level similar to electrostatically bound VEGF
in both transfected (PAE/KDR) and endogenous (HUVEC) cells
(Fig. 8).
Fig. 7. ELISA readings and release rates for VEGF immobilized to 1% EG-NH2, 1% EG-NH2/heparin-ABH (covalent), and 1% EG-NH2/heparin (electrostatic) surfaces. (A) Release curves
of VEGF showed that VEGF was stably bound to heparin-functionalized surfaces, but not to 1% EG-NH2 surfaces. (B) Direct ELISA measurements of VEGF on modiﬁed surfaces after
release conﬁrmed ﬁndings from SPR, with covalent and electrostatically bound VEGF immobilized at a density of 100 pg/cm2. (C) Release curves for electrostatically bound and
covalently bound VEGF in heparin (H, 1 mg/ml heparin) and PAE/KDR conditioned media (CM) show signiﬁcantly more release for electrostatically bound VEGF than for covalently
bound VEGF (p< 0.05). (D) Direct ELISA measurements of VEGF on surface after release conﬁrmed that covalently bound VEGF remained on surface while electrostatically bound
VEGF released. The symbol * indicates statistical signiﬁcance to a level of p< 0.05 using one-way ANOVA with a Tukey post-hoc test, which compares all possible pairs.
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ﬁrst immobilizing heparin to an amine containing SAM surface and
then immobilizing VEGF through its heparin-binding domain
(Fig. 1A). Covalently immobilized VEGF surfaces were generated
using the same general approach except that heparin was modiﬁed
with an amine reactive photoactivatable group that could be acti-
vated post-VEGF immobilization (Fig. 1B). Heparin was chosen
because it has been previously shown to bindwith VEGF through its
heparin-binding domain located at the C-terminus of the protein
[4] and because it can also bind ECM proteins such as ﬁbronectin
[32,33], collagen [34], vitronectin [35], and laminin [36]. The
binding of ECM proteins is essential to the study of VEGF/VEGFR-2
signaling cascades since the binding of cells through different
integrin receptors as well as the binding of VEGF with the ECM
molecules can modulate the signaling responses induced [33,37].
EG-NH2 and EG-OH terminated ethylene glycol thiols provided
a non-fouling surface in which to build our immobilized VEGF
surface since EG-OH terminated thiols have been previously
reported to prevent protein absorption [30,38] and cell binding
[29,38]. We found that the addition of the EG-NH2 did not increase
the amount of unspeciﬁc protein (Fig. 6) or cell binding (Fig. 5), but
allowed for the speciﬁc immobilization of oxidized heparin (Fig. 4).
Although ELISA analysis of the surface showed unspeciﬁc VEGFattachment to a 1% amine surface, it released quickly in PBS
(Fig. 7A) indicating that the interaction was not stable. Previous
reports have shown that UV can compromise the integrity of the
SAM surface through oxidation of the thiol groups [39], yet we
found that when the surface is submerged in PBS buffer and
exposed to UV light, as is the case when VEGF is immobilized
covalently on the surface, the SAM surface remains intact (Fig. 3A).
Although cell proliferation has been used to assess the activity of
the immobilized growth factor, cell proliferation is only an indirect
measure of VEGF activity and cannot guarantee that VEGFR-2 is
phosphorylated [3,12]. Since we are interested in using these
surfaces to study downstream signaling events, the ability of VEGF
to phosphorylate VEGFR-2 is essential. Thus, we used VEGFR-2
phosphorylation to assess VEGF activity in addition to cellular
proliferation. The phosphorylation of VEGFR-2 by electrostatically
and covalently immobilized VEGF suggests that VEGF retains some
activity. Background phosphorylation levels observed for the
negative control during PAE/KDR cell stimulation are a result of lack
of regulation of VEGFR-2 concentration at the cell surface since
PAE/KDR cells are stably transduced to overexpress VEGFR-2
(Fig. 8A). The lower intensity of the phosphorylation bands
observed for the surface-bound VEGF versus the soluble VEGF
condition for HUVECs (Fig. 8B) could be a result of several reasons.
Fig. 8. Western blot analysis of PAE/KDR cells (A) and HUVECs (B) brought into contact with VEGF-modiﬁed surfaces or exposed to soluble VEGF. (A) Top band shows phos-
phorylated VEGFR-2 (pVEGFR-2), while bottom band shows total VEGFR-2. Plot quantiﬁes phosphorylated VEGFR-2 band intensities and is normalized to total VEGFR-2 for each
condition (n¼ 5 blots). Surface-bound VEGF phosphorylates VEGFR-2 to a greater extent than background in the negative control. Soluble VEGF does not signiﬁcantly increase
phosphorylation signal over surface-bound VEGF. (B) Top band shows pVEGFR-2 and bottom band shows total VEGFR-2. Plot quantiﬁes phosphorylated VEGFR-2 band intensities
and is normalized to total VEGFR-2 for each condition (n¼ 3 blots, representative blot shown). Both electrostatically and covalently bound VEGF were able to phosphorylate VEGFR-
2 in PAE/KDR cells and HUVECs. The symbol * indicates statistical signiﬁcance to a level of p< 0.05 using one-way ANOVA with a Tukey post-hoc test, which compares all possible
pairs.
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immobilization process, or that HUVECs plated on PDMS as
opposed to tissue culture plastic have different phosphorylation
potential. Another possible explanation is that the slow or lack of
endocytosis of the VEGF/VEGFR-2 complex reduces the degree of
phosphorylation. Finally, bound VEGF and soluble VEGF could have
distinct kinetics of phosphorylation. To begin studying the reason
for the difference in phosphorylation strength, we investigated
VEGFR-2 phosphorylation for HUVECs placed in contact withFig. 9. Cell proliferation of HUVECs on VEGF-modiﬁed surfaces conﬁrms VEGF mitogen
activity in immobilized state. At day 5, the cell number on VEGF-modiﬁed surfaces is
signiﬁcantly greater than the cell count on the negative control. The symbol *, **, and
*** indicate statistical signiﬁcance to a level of p< 0.05, p< 0.01, and p< 0.001,
respectively, using one-way ANOVA with a Tukey post-hoc test, which compares all
possible pairs.soluble VEGF or VEGF-modiﬁed surfaces for 5 and 30 min. Soluble
VEGF-induced phosphorylation resulted in a dramatic decrease
from the 5-min time point to the 30-min time point, while surface-
bound VEGF-induced phosphorylation remained more constant
from the 5-min time point to the 30-min time point (Fig. 8B). These
results begin to suggest that the phosphorylation of VEGFR-2 by
immobilized VEGF has different kinetics than phosphorylation
induced by soluble VEGF. However, at this moment, it is not
possible for us to conclude the exact reason for the lower phos-
phorylation of VEGFR-2 in the immobilized VEGF conditions.
Notwithstanding, we can conclude that some of the immobilized
VEGF is active because it can phosphorylate VEGFR-2.
Although we have immobilized VEGF covalently, VEGF contains
a protease-sensitive site encoded by exon 5 directly preceding the
heparin-binding domain in the amino acid sequence [10]. Thus, it
could be argued that the VEGF is still being released from the
surface and that the phosphorylation observed occurs through
VEGF internalization. However, the release proﬁles of covalently
bound VEGF show that VEGF is ‘‘locked’’ into place through the
covalent crosslinker (Fig. 7C). Therefore, the VEGF release data and
the short duration of the cell-surface contact (5 or 30 min) indicate
that the phosphorylation band observed is due to covalently
immobilized VEGF. Further, these ﬁndings imply that VEGFR-2
phosphorylation can occur without internalization of the ligand/
receptor complex.
Previous studies of VEGF immobilization have relied on cellular
proliferation rather than receptor phosphorylation to verify VEGF
activity in the bound state [10,11]. Both electrostatically and cova-
lently bound VEGF resulted in increased cell density over the no
VEGF control after 5 days of culture (Fig. 9). While the cells did not
proliferate to the extent of the soluble VEGF condition, it is
important to note that the soluble concentration was orders of
magnitude more VEGF thanwhat has been observed on the surface
(100 pg/cm2 versus 200 ng/ml). Soluble and immobilized VEGF
Fig. 10. Fluorescent microscopy of HUVECs on VEGF-modiﬁed surfaces. Cells were stained for the nuclei (blue), actin (green) and PECAM-1 (CD31, red). HUVECs were plated on (A)
covalently bound VEGF and (B) electrostatically bound VEGF surfaces. As controls, HUVECs were plated on surfaces that contained heparin and ﬁbronectin but no bound VEGF (C,
negative control) and surfaces that were treated with soluble VEGF (200 ng/ml, positive control, D). Soluble VEGF treatment resulted in different morphology from the other
conditions with cells stretched and polarized in a single direction (D). (E) Quantiﬁcation of PECAM intensity showed an increase in intensity for surface-bound and soluble VEGF
over negative control. Scale bar is 100 mm. The symbols * and *** indicate statistical signiﬁcance to a level of p< 0.05 and p< 0.001 using one-way ANOVAwith a Tukey post-hoc test,
which compares all possible pairs.
S.M. Anderson et al. / Biomaterials 30 (2009) 4618–4628 4627may induce signaling that leads to different cell fates, which may
result in different proliferation rates depending on the afﬁnity of
the VEGF for the matrix. Indeed, bound VEGF and soluble VEGF lead
to differences in blood vessel structure in vivo [8].
HUVECs plated on VEGF-modiﬁed surfaces (both electrostatic
and covalent) and the no VEGF surface resulted in cobblestone cell
morphology (Fig. 10A–C), while HUVECs treated with soluble VEGF
resulted in cells becoming elongated after 5 days of culture
(Fig. 10D). Since it has been established that bound VEGF is activethrough VEGFR-2 phosphorylation, differences in cellular
morphology must be attributed to either the presentation of the
growth factor or the magnitude of the VEGF concentration avail-
able to the cell. PECAM staining of the cells revealed statistically
higher levels of PECAM stain for VEGF containing surfaces (p< at
least 0.05, Fig. 10E) over the negative control, but no statistical
difference between the VEGF treated conditions. Increased PECAM
expression is a downstream consequence of VEGF stimulation
[40].
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VEGF was covalently and electrostatically immobilized to a SAM
on gold surface and shown to remain active post-immobilization by
retaining its ability to phosphorylate VEGFR-2 in both transfected
and endogenous VEGFR-2 expressing cells. VEGF was covalently
immobilized to the surface using a bind-and-lock strategy. The
natural afﬁnity of VEGF for heparin was ﬁrst used to orient the
growth factor on the surface (bind) and then a photoreactive
heterobifunctional crosslinker generated a covalent bond between
the VEGF and the immobilized heparin upon activation (lock).
Similarly, electrostatically bound VEGF was immobilized using the
afﬁnity of VEGF for heparin, but without the use of the photo-
reactive crosslinker. Characterization of the surfaces showed that
electrostatically and covalently bound VEGF released at different
rates in conditioned cell culture medium, indicating that these
surfaces may be ideal to study VEGF/VEGFR-2 signaling as a func-
tion of growth factor afﬁnity for the ECM.Acknowledgements
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